Tharimmune, Inc. | WebDisclosure

Basculer en Français

8295	Companies
114863	Keywords
55304	Articles
62446	Press releases

Home
Companies
Tharimmune, Inc.

BRIEF

published on 10/30/2024 at 13:05, 21 days 23 hours ago

Tharimmune Secures EMA Feedback for TH104 in Chronic Pruritus

Chronic Pruritus Tharimmune PBC Treatment EMA Feedback TH104 Clinical Program
PRESS RELEASE

published on 10/30/2024 at 13:00, 21 days 23 hours ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive feedback from EMA on Phase 2 trial plans for TH104, a clinical candidate for pruritus in PBC, a rare liver disease

Tharimmune Inc. Phase 2 Trial PBC Pruritus European Medicines Agency
BRIEF

published on 10/28/2024 at 14:05, 23 days 22 hours ago

Tharimmune Reports Positive Phase 1 Results for TH104 at ACG Meeting

TH104 Phase 1 Trial Pruritus Chronic Liver Disease Clinical Safety
BRIEF

published on 10/28/2024 at 14:05, 23 days 22 hours ago

Tharimmune annonce des résultats positifs de phase 1 pour le TH104 lors de la réunion de l'ACG

TH104 Essai De Phase 1 Maladie Chronique Du Foie Prurit Sécurité Clinique
PRESS RELEASE

published on 10/28/2024 at 14:00, 23 days 22 hours ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile

TH104 Tharimmune Pruritus Chronic Liver Disease Phase 1 Data
BRIEF

published on 10/25/2024 at 14:05, 26 days 22 hours ago

Tharimmune présentera ses principales conclusions lors de prochaines conférences

Biotechnologie Conference Tharimmune Thérapeutique Immunologie
BRIEF

published on 10/25/2024 at 14:05, 26 days 22 hours ago

Tharimmune to Present Key Findings at Upcoming Conferences

Biotechnology Conference Therapeutics Tharimmune Immunology
PRESS RELEASE

published on 10/25/2024 at 14:00, 26 days 22 hours ago

Tharimmune Announces Upcoming Conference Presentations
Tharimmune, Inc. to present new results from Phase 1 trial of TH104 at ACG 2024 Annual Scientific Meeting. CEO to speak at 2024 ThinkEquity Conference in NY. Webcast available

Tharimmune Inc. Phase 1 Trial Clinical-stage Biotechnology ACG 2024 ThinkEquity Conference
BRIEF

published on 07/22/2024 at 14:35, 3 months 29 days ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Scientific Advisory Board TH104 Tharimmune David Jones Autoimmune Liver Disease
BRIEF

published on 07/22/2024 at 14:35, 3 months 29 days ago

Tharimmune nomme le professeur David Jones de l'Université de Newcastle à son conseil consultatif scientifique

TH104 Conseil Consultatif Scientifique Tharimmune David Jones Maladie Hépatique Auto-immune

Accesswire

Published on 11/21/2024 at 12:00, 43 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 43 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 13 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 40 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 43 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 8 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 28 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 37 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 43 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 13 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 45 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 36 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 23 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE